MedTrace Logo

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

NCT02754596 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2023-09-26

Study results available
· View outcomes & findings →

Summary

This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.

Conditions

  • Glaucoma Open-angle

Interventions

DRUG

Travoprost Intraocular Implant, high elution

Surgical implant placed within the eye to elute travoprost.

DRUG

Travoprost Intraocular Implant, low elution

Surgical implant placed within the eye to elute travoprost

DRUG

Timolol Maleate Ophthalmic Solution, 0.5%

Instillation of one drop of timolol in the study eye twice daily

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Kerry Stephens, O.D. · Glaukos Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-29
Primary Completion
2017-08-01
Completion
2020-07-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02754596 on ClinicalTrials.gov